Startup Claims Injectable Drug Reverses Blood Aging

Generation Lab, a startup in the longevity sector, has announced a new injectable treatment called 1-Generation, which it claims can reverse the aging process in the bloodstream. The treatment is described as a combination of two existing drugs designed to block the systemic spread of aging, reawaken the body's repair mechanisms, and restore youth to multiple tissues. Alina Su, CEO of Generation Lab, stated in a conference call that the company is excited to launch this therapeutic, asserting that it is the first longevity therapeutic to be administered in the human body and is already demonstrating efficacy. Su also indicated a significant waitlist for the treatment, including numerous celebrities and well-known individuals, suggesting high demand and interest.

The company's claims have garnered attention, partly due to its founder, Irina Conboy. Conboy is a recognized specialist in parabiosis, a scientific practice involving the joining of circulatory systems of old and young laboratory animals. Parabiosis has been scientifically validated as a method to make older animals exhibit younger physiological characteristics. The challenge in applying this research to humans lies in the impracticality of surgically connecting individuals. Generation Lab's 1-Generation treatment aims to replicate the benefits of parabiosis through a pharmaceutical approach, by identifying a specific combination of two existing drugs that can stimulate these rejuvenating effects without the need for surgical intervention.

Despite the promising claims, Generation Lab has not disclosed the identities of the two drugs that constitute 1-Generation. This lack of transparency makes it difficult for external scientific evaluation and raises questions about the scientific rigor and safety of the treatment. The company offered the author of the original report an exclusive opportunity to join a "private cohort" for early access to the treatment, emphasizing close physician supervision. This offer was presented as part of a marketing campaign targeting individuals whose judgment on the science is trusted. The company's approach, while leveraging established scientific principles like parabiosis, relies on proprietary drug combinations that are not yet publicly detailed or independently verified, positioning it within the speculative yet rapidly growing field of longevity medicine.